



Marinus Pharmaceuticals  
Investor Relations Department  
170 N. Radnor Chester Road,  
Suite 250  
Radnor, PA 19087-5279  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRNS

Last Trade:	2.81
Trade Time:	9:40 AM ET Aug 21, 2017
Change:	0.03 <span style="color: green;">▲</span> (+1.079%)
Day Range	2.71 - 2.83
52-Week Range	0.82 - 3.25
Volume	49,784


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 1, 2017*  
[Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results](#)
- Jun 29, 2017*  
[FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder](#)
- Jun 27, 2017*  
[Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression](#)
- May 1, 2017*  
[Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results](#)
- Apr 18, 2017*  
[Marinus to present Ganaxolone DATA at American academy of neurology annual meeting](#)

## Upcoming Events [\[ View all \]](#)

- Sep 6, 2017*  
[International Epilepsy Congress](#)
- Sep 25-27, 2017*  
[Cantor Fitzgerald's Global Healthcare Conference](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Mar 16, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)

## Financials & Filings [\[ View all \]](#)

[Second Quarter Financial Results](#)